Stephen Aherne, pharmaceuticals and life sciences leader at PwC, said:
“The number of strategic investments announced for the UK’s world-leading life sciences ecosystem are a positive step in the right direction to boost the growth of this strategic sector.
“However, the Budget was silent on the relationship between the NHS and life sciences industry, where greater partnerships and investment are critical levers in driving improved diagnosis, prevention and treatment of life threatening and chronic diseases, ultimately improving productivity and patient outcomes within the NHS.
“More partnerships with UK and international pharmaceutical and life sciences companies will be critical to ensuring UK businesses can thrive, grow and remain in the UK. This in turn is a vital part of the UK’s ongoing goal of truly becoming the world-leading life sciences superpower. We will also need a continued improvement in scale-up capital to support our small growing biotech companies, many of which remain in a precarious financial position.”
Spring Budget 2024
Follow our live coverage to see the reactions from our PwC Tax and economics experts
About PwC
At PwC, we help clients build trust and reinvent so they can turn complexity into competitive advantage. We’re a tech-forward, people-empowered network with more than 364,000 people in 136 countries and 137 territories. Across audit and assurance, tax and legal, deals and consulting, we help clients build, accelerate, and sustain momentum. Find out more at pwc.com.
© 2025 PwC. All rights reserved.
Contact us
